Document Detail


The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
MedLine Citation:
PMID:  18657224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Histone deacetylase (HDAC) inhibitors represent a promising class of antineoplastic agents which affect tumour growth, differentiation and invasion. The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro and in vivo on pre-clinical renal cell carcinoma (RCC) models. Caki-1, KTC-26 or A498 cells were treated with various concentrations of VPA during in vitro cell proliferation 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays and to evaluate cell cycle manipulation. In vivo tumour growth was conducted in subcutaneous xenograft mouse models. The anti-tumoural potential of VPA combined with low-dosed interferon-alpha (IFN-alpha) was also investigated. VPA significantly and dose-dependently up-regulated histones H3 and H4 acetylation and caused growth arrest in RCC cells. VPA altered cell cycle regulating proteins, in particular CDK2, cyclin B, cyclin D3, p21 and Rb. In vivo, VPA significantly inhibited the growth of Caki-1 in subcutaneous xenografts, accompanied by a strong accumulation of p21 and bax in tissue specimens of VPA-treated animals. VPA-IFN-alpha combination markedly enhanced the effects of VPA monotherapy on RCC proliferation in vitro, but did not further enhance the anti-tumoural potential of VPA in vivo. VPA was found to have profound effects on RCC cell growth, lending support to the initiation of clinical testing of VPA for treating advanced RCC.
Authors:
Jon Jones; Eva Juengel; Ausra Mickuckyte; Lukasz Hudak; Steffen Wedel; Dietger Jonas; Roman A Blaheta
Related Documents :
9845114 - The influence of elevated levels of platelet-derived endothelial cell growth factor/thy...
2001334 - Quantitative evaluation of the tumour-stroma border by exponential regression analysis.
9363454 - Adenomyoepithelioma of the skin: a case report with immunohistochemical and ultrastruct...
18336194 - Ubiquitylation and cancer development.
12686474 - Endothelin-1 directly modulates its own secretion: studies utilising the cell immunoblo...
22674854 - Restoration of caveolin-1 expression suppresses growth, membrane-type-4 metalloproteina...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-07-24
Journal Detail:
Title:  Journal of cellular and molecular medicine     Volume:  13     ISSN:  1582-4934     ISO Abbreviation:  J. Cell. Mol. Med.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2010-02-09     Completed Date:  2010-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101083777     Medline TA:  J Cell Mol Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  2376-85     Citation Subset:  IM    
Affiliation:
Department of Urology and Pediatric Urology, Goethe-University, Frankfurt am Main, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Carcinoma, Renal Cell / pathology*
Cell Division / drug effects*
Histone Deacetylase Inhibitors / pharmacology*
Humans
Kidney Neoplasms / pathology*
Mice
Valproic Acid / pharmacology*
Chemical
Reg. No./Substance:
0/Histone Deacetylase Inhibitors; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Importins and exportins in cellular differentiation.
Next Document:  CHEMOTHERAPY DRUG RESPONSE IN OVARIAN CANCER CELLS STRICTLY DEPENDS ON A CATHEPSIN D - BAX ACTIVATIO...